BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026

BridgeBio (Nasdaq: BBIO) will present additional positive data from PROPEL 3, its global Phase 3 trial of oral infigratinib in children with achondroplasia, at ICCBH 2026 in Montreal, June 27–30, 2026.

Rhea-AI Summary

BridgeBio (Nasdaq: BBIO) will present additional positive data from PROPEL 3, its global Phase 3 trial of oral infigratinib in children with achondroplasia, at ICCBH 2026 in Montreal, June 27–30, 2026.

The company will also deliver one oral presentation and multiple posters on achondroplasia, hypochondroplasia, and autosomal dominant hypocalcemia (ADH1/ADH2).

Argus Jun 22 session

+4.00% close to close Open Argus

Details

News Market Reaction – BBIO

On Jun 22, the day this news came out, BBIO closed 4.00% above the previous close.

Data tracked by StockTitan Argus for the Jun 22 session.

Market Context

This announcement extends BBIO’s achondroplasia program with detailed PROPEL 3 presentations and anc...

Analysis

This announcement extends BBIO’s achondroplasia program with detailed PROPEL 3 presentations and ancillary studies, reinforcing a multi‑asset late‑stage pipeline. Investors may watch how these data complement prior Phase 3 results and interact with ATM and short‑interest overhangs near ICCBH 2026.

Key Figures

Conference dates: June 27–30, 2026 Late-breaking oral time: June 28, 3:45 pm EDT Quality-of-life oral time: June 29, 11:00 am EDT +2 more

Conference dates

June 27–30, 2026

ICCBH 2026 meeting in Montreal

Late-breaking oral time

June 28, 3:45 pm EDT

Primary PROPEL 3 infigratinib results presentation

Quality-of-life oral time

June 29, 11:00 am EDT

Health-related quality of life PROPEL observational talk

Skeletal dysplasia posters

4 posters

Achondroplasia and hypochondroplasia research at ICCBH 2026

Phase designation

Phase 3

PROPEL 3 pivotal infigratinib trial in achondroplasia

Previous Clinical trial Reports

5 past events · Latest: May 5

Same Type 5 events

1. May 5

   Conference data preview

   24h Move

   -0.3%

   Announcement of upcoming Phase 3 CALIBRATE encaleret results at ECE 2026.

2. Mar 11

   Interim efficacy data

   24h Move

   -3.9%

   Positive Phase 3 FORTIFY interim efficacy and safety data for BBP-418 in LGMD2I/R9.

3. Mar 4

   Conference data update

   24h Move

   +3.1%

   Planned additional Phase 3 FORTIFY interim data presentations at MDA conference.

4. Feb 12

   Topline infigratinib data

   24h Move

   +3.7%

   Positive Phase 3 PROPEL 3 topline results for oral infigratinib in achondroplasia.

5. Oct 29

   Topline encaleret data

   24h Move

   +3.3%

   Positive Phase 3 CALIBRATE topline results for encaleret in ADH1 patients.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

randomized controlled trial, autosomal dominant hypocalcemia, observational study, patient-reported outcome measures, +1 more

5 terms

randomized controlled trial medical

"Late-Breaking Oral Presentation:A Randomized Controlled Trial of Oral Infigratinib in Children"

A randomized controlled trial is a research method that tests the effects of a new idea or treatment by randomly dividing participants into two groups: one that receives the treatment and one that does not. This approach helps ensure that the results are fair and unbiased, providing clear evidence about whether the treatment actually works. Investors value such trials because they offer reliable information that can influence decision-making and reduce uncertainty.

autosomal dominant hypocalcemia medical

"autosomal dominant hypocalcemia type 1 (ADH1) poster on findings from CLARIFY, its disease monitoring study of autosomal dominant hypocalcemia"

A inherited condition in which a single faulty gene makes the body keep blood calcium too low, causing muscle cramps, numbness or fatigue; think of a thermostat set too low so the house never warms properly. It matters to investors because it creates a predictable patient group and ongoing need for diagnostics, monitoring and treatments, making related drugs, tests or devices potential commercial opportunities.

observational study medical

"The ACCEL Observational Study: Diagnostic Features, Medical History, and Baseline Characteristics"

An observational study is a type of research where investigators watch and record what happens to people who are already using a treatment or experiencing a condition, without assigning who gets what. Think of it like monitoring shoppers in a store rather than giving some a special product and others not. For investors, these studies provide real‑world evidence about safety, effectiveness and market use that can influence regulatory decisions, sales forecasts and perceived risk.

patient-reported outcome measures medical

"Qualitative Research to Evaluate the Content Validity and Relevance of Patient-Reported Outcome Measures for Children"

Patient-reported outcome measures are standardized questionnaires or tools that capture a person’s own report of their symptoms, daily functioning, and quality of life without a clinician interpreting those answers. They matter to investors because these direct reports can drive regulatory approvals, product labeling, reimbursement decisions and market acceptance—think of them as customer reviews that regulators and payers use to judge whether a treatment truly helps patients.

phase 2/2b medical

"A Phase 2/2b Study of Infigratinib in Children Under 3 Years Old with Achondroplasia"

Phase 2/2b denotes mid-stage clinical studies that test whether a new drug or treatment works in patients and what dose is best. Phase 2 often explores safety and early signs of benefit in a smaller group, while a Phase 2b is a larger, more rigorous test focused on confirming the right dose and proof of effect before a costly, definitive Phase 3 trial. Investors watch these results because positive Phase 2/2b data meaningfully reduce scientific and commercial uncertainty and can materially change a company’s valuation; negative results raise risk and can sharply lower prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional positive data from PROPEL 3, the global Phase 3 pivotal study of oral infigratinib in children living with achondroplasia, will be shared in a late breaking oral presentation at the International Congress of Children’s Bone Health (ICCBH) 2026 taking place in Montreal, Canada on June 27-30, 2026.

BridgeBio will also share an oral presentation and four posters at the meeting highlighting quality of life, early intervention research, observational study findings, and educational resources through MyAchonJourney for individuals with achondroplasia and related skeletal dysplasias. Additionally, the Company will share an autosomal dominant hypocalcemia type 1 (ADH1) poster on findings from CLARIFY, its disease monitoring study of autosomal dominant hypocalcemia (ADH) type 1 and type 2.

Late-Breaking Oral Presentation:
A Randomized Controlled Trial of Oral Infigratinib in Children with Achondroplasia
Presenter: Ravi Savarirayan, M.D., Ph.D. of Murdoch Children’s Research Institute, Melbourne, AU, and Global Lead Investigator for PROPEL 3
Date & Time: Sunday, June 28 at 3:45 pm EDT

Oral Presentation:
Health-Related Quality of Life in Children with Achondroplasia: Findings from the Observational PROPEL Study
Presenter: Marie-Eve Robinson, M.D., M. Sc., Shriners Hospital for Children Canada, McGill University, CA
Date & Time: Monday, June 29 at 11:00 am EDT

Skeletal Dysplasia Posters:
A Phase 2/2b Study of Infigratinib in Children Under 3 Years Old with Achondroplasia: Design of PROPEL Infant and Toddler
Presenter: Julie Hoover-Fong, M.D., Ph.D., Johns Hopkins University, U.S.
Date & Time: Sunday, June 28 at 12:00 pm EDT

The ACCEL Observational Study: Diagnostic Features, Medical History, and Baseline Characteristics of Children with Hypochondroplasia
Presenter: Marie-Eve Robinson, M.D., M. Sc., Shriners Hospital for Children Canada, McGill University, CA
Date & Time: Monday, June 29 at 12:00 pm EDT

MyAchonJourney: An Online Educational Resource for Individuals with Achondroplasia and Their Families, Developed by Advocacy Leaders and Healthcare Providers
Presenter: Kirsten Kiefer, BridgeBio Skeletal Dysplasias, U.S.
Date & Time: Monday, June 29 at 12:00 pm EDT

Qualitative Research to Evaluate the Content Validity and Relevance of Patient-Reported Outcome Measures for Children and Parents of Children with Hypochondroplasia
Presenter: Chandler Crews, The Chandler Project, U.S.
Date & Time: Monday, June 29 at 12:00 pm EDT

ADH1 Poster:
Autosomal Dominant Hypocalcemia Type 1 and Type 2: Baseline Burden of Disease and Quality of Life in Pediatric Participants in the CLARIFY Disease Monitoring Study
Presenter: Raja Padidela, M.D., Royal Manchester Children's Hospital, University of Manchester, UK
Date & Time: Monday, June 29 at 12:00 pm EDT

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will BridgeBio (Nasdaq: BBIO) present from the PROPEL 3 trial at ICCBH 2026?

BridgeBio will present additional positive primary results from the Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia. According to BridgeBio, these data will be shared in a late-breaking oral session at ICCBH 2026 in Montreal.

When is BridgeBio presenting PROPEL 3 Phase 3 achondroplasia data at ICCBH 2026?

BridgeBio’s late-breaking oral presentation on PROPEL 3 is scheduled for Sunday, June 28, 2026, at 3:45 pm EDT. According to BridgeBio, this randomized controlled trial presentation will focus on oral infigratinib in children living with achondroplasia.

Which other BridgeBio achondroplasia studies are featured at ICCBH 2026 for BBIO?

BridgeBio will highlight PROPEL observational study quality-of-life data and the PROPEL Infant and Toddler study design. According to BridgeBio, it will also present MyAchonJourney educational resources and qualitative research on patient-reported outcomes in children with hypochondroplasia.

What is the MyAchonJourney resource BridgeBio is showcasing at ICCBH 2026?

MyAchonJourney is an online educational resource for individuals with achondroplasia and their families. According to BridgeBio, advocacy leaders and healthcare providers developed the platform, and related findings will be presented in a poster session on Monday, June 29, 2026, at 12:00 pm EDT.

What hypochondroplasia research related to BBIO is being presented at ICCBH 2026?

BridgeBio-associated investigators will present the ACCEL observational study and qualitative research on hypochondroplasia. According to BridgeBio, these works cover diagnostic features, baseline characteristics, and patient-reported outcome measures for children and parents of children with hypochondroplasia.

What is BridgeBio presenting on autosomal dominant hypocalcemia (ADH1/ADH2) at ICCBH 2026?

BridgeBio will share a CLARIFY disease monitoring study poster on autosomal dominant hypocalcemia types 1 and 2. According to BridgeBio, the poster describes baseline burden of disease and quality of life in pediatric participants, presented Monday, June 29, 2026, at 12:00 pm EDT.